News Archive

October 7, 2024

Judo Bio debuts with $100M and a plan to take RNA drugs to the kidney

  • Portfolio Company News
Read more
October 2, 2024

With $115M more, Triveni accelerates immune drug work

  • Portfolio Company News
Read more
October 1, 2024

Ron Renaud’s new obesity biotech, Kailera, has $400M to go straight to Phase 3

  • Portfolio Company News
Read more
September 26, 2024

Endpoints 11 winner Lifordi Immunotherapeutics: Using antibodies to deliver potent steroids directly to immune cells

  • Portfolio Company News
Read more
September 18, 2024

Reflections On My Experience As A Board Member

  • From the Trenches
Read more